Failure-free survival, defined as absence of relapse, non-relapse mortality or addition of another systemic therapy, has been proposed as a potential endpoint for clinical trials, but it has only been reported for single center studies. We measured failure free survival in a prospective observational cohort of patients with both newly diagnosed and existing chronic graft-versushost disease (n=575) from nine centers. Failure was observed in 389 (68%) during the observation period. Median follow up of all patients was 30.9 months, and median failure free survival was 9.8 months (63% at 6 months, 45% at one year, and 29% at two years). Of the variables measured at enrollment, ten were associated with shorter failure free survival: higher NIH 0-3 skin score, higher NIH 0-3 GI score, worse range of motion summary score, lower forced vital capacity (%), bronchiolitis obliterans syndrome, worse quality of life, moderate to severe hepatic dysfunction, absence of treatment for gastric acid, female donor into male patient, and prior grade II-IV acute graft-versus-host disease. Addition of a new systemic treatment, the major cause of failure, was associated with an increased risk of subsequent nonrelapse mortality (HR=2.06, 95%CI: 1.29-3.32, p<0.003) and decreased survival (HR=1.51, 95%CI: 1.04-2.18, p<0.03). These results show fewer than half of patients on systemic treatment will be failure-free survivors at one year, and fewer than a third will reach two years without experiencing failure. Better treatments are needed for chronic graft-versus-host disease.
determined retrospectively by chart review for prevalent cases. The median time of follow up for survivors was 30.9 months (range: 0.9-65.8 months). Of the 53 patients with "mild chronic GVHD or less," 51 had mild chronic GVHD while 2 technically had less than mild, meaning that they scored a 0 in all organ scores, even though they met the NIH diagnostic criteria for chronic GVHD. Failure-free survival for the entire cohort was 63% at 6 months, 45% at one year, and 29% at two years. (Figure 1 ) Among the 575 patients, 389 experienced failure due to addition of systemic therapy (n=300, 77%), relapse (n=54, 14%) and non-relapse mortality (n=35, 9%), Figure 2 . For the entire study cohort, median FFS was 9.8 months (95% CI 9.0-11.7) ( Table 2) .
When analyzed separately, incident cases had a trend suggesting shorter median FFS than prevalent cases (9.2 months vs. 11.6 months; p=0.18). NIH global severity at enrollment was associated with FFS. Patients with severe chronic GVHD had a median FFS of 8.5 months (95% CI 5.6-9.6), whereas those with moderate and mild severity had a median FFS of 11.7 months (95% CI 9.3 -16.8) and 14.9 months (95% CI 8.3 -23.3) respectively (p<0.001, Table   2 and Figure 1 ). When relapse was excluded from the definition of failure, median FFS was approximately one month longer (11.0 months, 95% CI 9.3-14.8).
Risk Factors associated with Failure-free survival
All tested variables are reported in the supplemental table 1. Supplementary table 2 shows the results of univariable and multivariable analysis for each organ system. Table 3 shows the factors that were statistically associated with FFS at p≤0.05 in multivariable analysis including all variables identified in the organ-specific analysis. Two variables precede the diagnosis of chronic GVHD: female donor into male recipient and history of grade II-IV acute GVHD and are associated with a higher risk of failure. Four factors directly measure GVHD severity (higher NIH 0-3 skin score, higher NIH 0-3 GI score, worse (lower) ROM joint scores, presence of bronchiolitis obliterans syndrome [BOS] ) and are associated with a higher risk of failure. Higher scores on one laboratory test (FVC) and one measure of quality of life, the FACT BMT TOI (Functional Assessment of Cancer Therapy Bone Marrow Transplant module, Trial Outcome Index) were associated with better functioning and a lower risk of failure. Two comorbidities were also associated with FFS: The presence of moderate to severe hepatic dysfunction defined as liver cirrhosis, total serum bilirubin concentration > 1.5 times upper limit of normal (ULN) or transaminase concentration > 2.5 times ULN was associated with shorter FFS, while a co-morbidity of peptic ulcer disease, hiatial hernia, reflux disease, or treatment with an acid reducing agent was associated with longer FFS. Notably, incident vs. prevalent case status at time of enrollment was not associated with FFS. No statistically significant interactions were detected between significant variables in the multivariate analysis.
Addition of systemic immunosuppressive medication
Addition of new systemic treatment for chronic GVHD accounted for most of the failure events.
A time-varying Cox regression analysis showed that addition of a new medication was associated with increased risks of overall mortality (HR=1.51, 95%CI: 1.04-2.18, p=0.03) and non-relapse mortality (HR=2.06, 95%CI: 1.29-3.32, p=0.003).
Discussion
In this study, we used a prospectively studied multicenter cohort of patients with chronic GVHD to explore the parameters of FFS and to characterize the factors that predict failure. We identified ten factors, including pre-transplant variables, female donor into male recipient and history of grade II-IV acute GVHD, laboratory values, including a co-morbidity of hepatic dysfunction defined by liver function tests and lower FVC, and clinical findings including higher NIH 0-3 skin score, high NIH 0-3 GI score, worse ROM score, absence of GI co-morbidity of peptic ulcer disease, hiatal hernia, or reflux disease, and presence of BOS that predict shorter FFS. Shorter FFS was also associated with worse quality of life (lower score) on the FACT BMT TOI. Of note both FVC and the FACT BMT TOI had hazard ratios close to 1 because these scales are continuous with a large dynamic range. In our cohort, FFS was 63% at six months, 45% at one year, and 29% at two years, which are similar to proportions observed in previous studies.(9, 10) Additionally, we demonstrate that an addition of a new treatment was associated with higher non-relapse and overall mortality, which is in agreement with previous studies. (14, 15) Inamoto et al. published two analyses of FFS in patients who received first-line(9) or second-line therapy for chronic GVHD at a single institution.(10) The median duration of FFS and the rates of FFS at six months and two years in the current study are similar their results(9, 10) despite the differences in cohort definition. Failure of first line therapy was associated with grade 3 lower GI, liver or lung involvement, KPS <80% at enrollment, age >60, and shorter interval between transplant and onset of chronic GVHD.(9) Failure of second line therapy was associated with higher disease risk at the time of transplant, lower GI involvement and severe chronic GVHD.(10) The factors that predicted FFS were similar in our study, including lower GI involvement, and lung involvement. Although liver involvement did not predict outcome, hepatic comorbidity did predict FFS. Both are defined by liver function test abnormalities, although the thresholds differ. Global chronic GVHD severity was significant in our univariate analysis but was not included in the final multivariate analysis due to the overlap with organ-specific information. Finally, KPS and age were not found to be significantly associated with outcome in our analysis. There were some shared patients in the two cohorts. Forty eight (8%) of the patients in our study were also included in the Inamoto secondary analysis cohort,(10) although these patients were analyzed at different times in the course of their chronic GVHD. There was a higher degree of overlap with the FFS analysis performed for first line therapy,(9) where 167 (29%) of patients overlapped with our cohort. However, when patients shared with the Inamoto study were excluded, the results are unchanged (data not shown).
Our study confirms that skin, joint, GI, lung and liver severity predict failure-free survival, which is driven primarily by treatment changes. These characteristics have also been reported to be important in other analyses evaluating predictors of survival. For example, lower GI and liver involvement have been shown to be associated with an inferior survival when considered alone (16) The organs that were not associated with FFS: eye, mouth and genital involvement, should be noted. This finding is not unexpected as these organs usually are treated with topical therapy. . However, it is notable that factors historically associated with a worse outcome in chronic GVHD, such as low platelets, lower KPS, and progressive onset were significant in univariate analysis, but not in the organ specific or overall multivariate analyses. The reason for these discrepant findings may be due to differences in endpoint (six month FFS vs. non-relapse mortality or survival) or analysis approach. In general, we were able to consider many more potentially predictive variables than prior analysis because of our detailed data collection.
Finally, disease status at transplant and age were not found to be significantly associated with FFS in our analysis.
Strengths of our study include the large number of patients evaluated, the prospective collection of detailed data from multiple centers, and the comprehensive consideration of variables in regression analyses. Two limitations should be highlighted. Enrollment in the cohort did not depend on treatment status. The cohort included patients with minimal or longer-term stable immunosuppressive regimens and patients with much more intensive treatment or several prior lines of therapy, resulting in a heterogenous patient population with different risks of failure. We did not have accurate information regarding the number of lines of therapy nor the intensity of the therapies. Regardless, we did not detect significant differences according to several classification systems, including incident vs. prevalent cases or classic vs. overlap subtype.
Second, the reasons for treatment changes were not recorded. For example, we could not determine whether a given change from tacrolimus to mycophenolate mofetil was related to toxicity such as thrombotic microangiopathy or neurotoxicity, or whether the change was prompted by ineffectiveness of the first medication. This has been a criticism of the FFS endpoint for clinical trials. Nevertheless, patients in clinical trials who have systemic treatment added for any reason are usually considered treatment failures, and the absence of new treatment serves as a minimal requirement for success when the primary endpoint is assessed.
The heterogeneity of our population may serve as both a strength and a limitation. Different transplant centers likely have different practices regarding steroid tapers which may affect the failure rates. Specific steroid doses were not available unless they were given as high dose regimens. Additionally, the clinical trial portfolio varies from center to center, and one reason to start new therapy may be the option to provide a novel therapy on a clinical trial. Although these are potential confounders, they will also increase the generalizability of our findings as they are more likely to be represent the variety of patients who would be enrolled in a multicenter clinical trial. It is notable that our findings were similar to those observed by Inamoto et al (9, 10)in a more homogeneous population that had minimal overlap.
There were two findings that were somewhat unexpected. First, presence of a co-morbidity of 1 0 prolonged FFS. As patients who were on acid reducing medications were also considered to have this co-morbidity, it may reflect higher doses or more prolonged treatment with glucocorticoids. We were unable to analyze steroid doses with the available data. There did not appear to be an association between peptic ulcer comorbidity and NIH global severity (data not shown). Second, overlap syndrome was not associated with shorter FFS. Previous studies have demonstrated that overlap syndrome is associated with decreased overall survival.
However, half the failures occurred within the first year and were primarily due to treatment change, not death, potentially explaining why our current results differ from prior reports.
One may question whether relapse should be considered a failure of chronic GVHD therapy, as the risk of relapse depends more on the malignant disease risk rather than any features of chronic GVHD. In agreement with Inamoto et al.,(9, 10) we included this component in the endpoint, because potent immunosuppression that could control GVHD could increase the risk of relapse. When we reanalyzed the data excluding relapse from the definition of failure, the median FFS was only 1 month longer (data not shown). Additionally, disease relapse contributed to only a minority of the failures, and disease risk did not have a statistically significant association with FFS in the univariate analysis, suggesting that disease relapse is not a major driver of the duration of FFS.
In summary, FFS correlates with subsequent non-relapse mortality and survival. Absence of these failure events should recognized as the minimal definition of success for an investigational agent. Our results highlight the poor outcomes in patients with chronic GVHD and the unsatisfactory ability of currently available therapies to adequately control the disease. By six months after enrollment into our study, a third of patients had already been started on new systemic agents, relapsed or died. By 12 months after enrollment, more than half had failed in one of these ways, and by two years after enrollment only 30% of patients had not relapsed, 1 1 died, or started another treatment. These results clearly illustrate the need for new, more effective, and less toxic therapies for chronic GVHD.
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